Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens its fragment library using both its proprietary Target Immobilized NMR Screening and SPR capabilities…
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
MILAN, IT, AND LEIDEN, NL
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading…